CTHRC1 and gastric adenocarcinoma: Additionally, we have also identified few potential drugs that could influence the expression level of CTHRC1 in cancer, however, whether HNSC, KIRC, LIHC, LUAD, STAD, and UCEC patients with overexpressed CTHRC1 can benefit from these drugs or whether CTHRC1 may be targeted by these drugs in the treatment of these cancers needs biological experimental support.